SK3 Group, Inc. (SKTO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.00 means the share price is 0.00 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSK3 Group, Inc. (SKTO) trades at $0.00001. SK3 Group, Inc. operates within the medical marijuana sector, providing management advisory, licensing, and marketing services. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SKTO: SKTO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
SK3 Group, Inc. (SKTO) Healthcare & Pipeline Overview
SK3 Group, Inc. provides management, licensing, and marketing services to medical marijuana collectives in California, focusing on proprietary technologies and licensed products such as edibles and delivery systems. The company operates in a highly regulated and evolving market within the specialty and generic drug manufacturing industry.
What Is the Investment Thesis for SKTO?
SK3 Group, Inc. operates in the niche market of providing services to medical marijuana collectives in California. With a market capitalization of $0.00B, the company's financial performance, indicated by a profit margin of 0.3% and a gross margin of 71.9%, suggests potential for improvement in operational efficiency and revenue generation. The negative free cash flow of $-0.00B indicates a need for careful cash management. The company's beta of -24.08 suggests an inverse correlation with the market. Growth catalysts include the potential expansion of its licensing agreements and the increasing acceptance of medical marijuana. Key risks include regulatory changes and competition from larger players in the cannabis industry.
Based on FMP financials and quantitative analysis
SKTO Key Highlights
Gross margin of 71.9% indicates strong pricing power in its licensing and marketing services.
- Profit margin of 0.3% suggests potential for improved operational efficiency.
- Negative free cash flow of $-0.00B requires careful monitoring of cash management.
- Beta of -24.08 indicates an inverse correlation with the market.
- The company operates as a subsidiary of Healthcare of Today, Inc.
Who Are SKTO's Competitors?
SKTO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SKTO's Key Strengths?
Proprietary Dharmanol technology.
- Established presence in the California medical marijuana market.
- Licensing agreements for various medical marijuana products.
- Focus on management advisory services for collectives.
What Are SKTO's Weaknesses?
Small market capitalization.
- Limited geographic reach (California only).
- Dependence on the regulatory environment of California.
- Negative free cash flow.
What Are the Key Risks for SKTO?
Changes in California state regulations regarding medical marijuana could negatively impact operations.
- Increased competition from larger cannabis companies with greater resources.
- Negative free cash flow requires careful monitoring and management.
- Product liability claims related to medical marijuana products.
What Are SKTO's Competitive Advantages?
- Proprietary Dharmanol technology for cannabinoid extraction and preservation.
- Established relationships with medical marijuana collectives in California.
- Licensing agreements for unique medical marijuana products.
What Does SKTO Do?
Founded in 2000 and formerly known as CTT International Distributors, Inc., SK3 Group, Inc. shifted its focus to the medical marijuana sector in 2007. Headquartered in Los Angeles, California, the company operates as a subsidiary of Healthcare of Today, Inc. SK3 Group, Inc. specializes in providing management advisory, licensing, and marketing services to medical marijuana collectives within California. Its core business revolves around licensing various products, including the YAK line of medical marijuana edibles, Canna-Loz, a delivery system for phyto-cannabinoids, and Yeti, a pre-roll product designed for pain relief. A key element of their offerings is Dharmanol, a proprietary technology focused on the extraction, stabilization, and preservation of medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. The company's activities are concentrated within the California market, navigating the state's specific regulatory landscape for medical marijuana.
What Products and Services Does SKTO Offer?
- Provides management advisory services to medical marijuana collectives.
- Licenses medical marijuana-related products for marketing and sale.
- Offers the YAK line of medical marijuana edibles.
- Provides Canna-Loz, a delivery system for phyto-cannabinoids.
- Licenses Yeti, a pre-roll product for pain relief.
- Offers Dharmanol, a proprietary technology for cannabinoid extraction and preservation.
How Does SKTO Make Money?
- Generates revenue through licensing fees from medical marijuana products.
- Provides management advisory services to medical marijuana collectives for a fee.
- Markets and sells licensed products through established distribution channels.
What Industry Does SKTO Operate In?
SK3 Group, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, specifically catering to the medical marijuana sector in California. This industry is characterized by evolving regulations, increasing competition, and growing market acceptance of cannabis-based products for medicinal use. The company's focus on licensing and marketing services positions it within a segment that supports the broader cultivation, processing, and distribution activities within the cannabis value chain. The industry faces ongoing challenges related to federal regulations, interstate commerce restrictions, and the need for standardized quality control measures.
Who Are SKTO's Key Customers?
- Medical marijuana collectives in California.
- Patients seeking medical marijuana products for various conditions.
- Distributors of medical marijuana products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for SK3 Group, Inc. stands at 133.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 59.6%, showing how much profit it generates from its asset base. SKTO trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.10x. A current ratio of 10.04 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
SK3 Group, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Artemus Mayor. SKTO has traded publicly since 2008.
Financial Health
SK3 Group, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
SKTO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SKTO Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Oct 21, 2019
SKTO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SKTO.
Price Targets
Wall Street price target analysis for SKTO.
SKTO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SKTO; grades run from A+ (80-100) to F (below 30).
SKTO OTC Market Information
SKTO trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
SK3 Group, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for SKTO?
The main risks for SK3 Group, Inc. include regulatory changes in California and at the federal level, increased competition from larger cannabis companies, and potential product liability claims. As a small company operating in a highly regulated industry, SK3 Group, Inc. is vulnerable to shifts in the legal landscape. Increased competition could erode its market share and pricing power.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's size and OTC listing.